The Russian Direct Investment Fund (RDIF) highlighted the publication in the British medical journal The Lancet of the joint study of the Gamaleya National Research Center of Epidemiology and Microbiology and the Moscow City Center for AIDS Prevention and Control that confirmed such a result.
Based on the research with data from more than 24 000 HIV+ patients under antiretroviral therapy (ART), the article reflected that the efficacy of the Russian drug against the infection is 79 percent.
The scientific results presented in the text Sputnik V Protection against Covid-19 in people living with HIV on ART are the first on the preventive efficacy of an anti-Covid-19 vaccine to protect against infection in people living with the human immunodeficiency virus.
According to the authors of this research, full immunization with the Russian drug in HIV+ patients receiving ART with CD4+ T-cell counts ? 350/µl, resulted in a 3. 3-times reduction in the number of Covid-19 infections compared to non-immunized patients.
In the subgroup of patients with compromised immune function (CD4+ T cells < 350/µl) vaccination reduced the risk of Covid-19 by 2. 5 times.
World Health Organization data previously reflected that more than 23 percent of hospitalized HIV+ persons with Covid-19 died.
RDIF said the research published in The Lancet suggests that Sputnik V may be the ultimate solution for vulnerable groups, even in countries with high HIV prevalence.